CD8A and neoplasm: In the phase 1 trial, we reported that intratumoral injection of gene-modified dendritic cells induced a systemic tumor-specific immune response, enhanced tumor CD8+ T-cell infiltration (54% of all patients), and increased tumor programmed death-ligand 1 expression.17